153 related articles for article (PubMed ID: 2866563)
1. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
[TBL] [Abstract][Full Text] [Related]
2. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of central dopamine receptors in schizophrenia.
Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
[TBL] [Abstract][Full Text] [Related]
4. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
Hietala J; Koulu M; Scheinin M; Syvälahti E
Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
[TBL] [Abstract][Full Text] [Related]
6. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
Kolakowska T; Gelder M; Fraser S
Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
[TBL] [Abstract][Full Text] [Related]
8. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.
Nair NP; Lal S; Cervantes P; Yassa R; Guyda H
Neuropsychobiology; 1979; 5(3):136-42. PubMed ID: 431802
[TBL] [Abstract][Full Text] [Related]
9. Effect of apomorphine infusion on plasma homovanillic acid in normal subjects.
Davidson M; Kendler KS; Mohs RC; Hollander E; Ryan T; Davis KL
J Psychiatr Res; 1986; 20(2):131-5. PubMed ID: 3735141
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced growth hormone and prolactin responses in schizophrenia research.
Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man.
Lal S; Nair NP; Eugenio H; Thavundayil J; Lizondo E; Wood PL; Etienne P; Guyda H
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):537-44. PubMed ID: 6320299
[TBL] [Abstract][Full Text] [Related]
12. A neuroendocrine study of supersensitivity in tardive dyskinesia.
Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
[TBL] [Abstract][Full Text] [Related]
13. Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients.
Cutler NR; Jeste DV; Karoum F; Wyatt RJ
Life Sci; 1982 Mar; 30(9):753-6. PubMed ID: 7070229
[TBL] [Abstract][Full Text] [Related]
14. Hormones, dopamine receptors and schizophrenia.
Meltzer HY; Busch D; Fang VS
Psychoneuroendocrinology; 1981; 6(1):17-36. PubMed ID: 7244055
[No Abstract] [Full Text] [Related]
15. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
[TBL] [Abstract][Full Text] [Related]
16. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
Meltzer HY; Lee MA; Jayathilake K
Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
Rotrosen J; Angrist B; Gershon S; Paquin J; Branchey L; Oleshansky M; Halpern F; Sachar EJ
Br J Psychiatry; 1979 Nov; 135():444-56. PubMed ID: 540209
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic sensitivity and cocaine abuse: response to apomorphine.
Hollander E; Nunes E; DeCaria CM; Quitkin FM; Cooper T; Wager S; Klein DF
Psychiatry Res; 1990 Aug; 33(2):161-9. PubMed ID: 2243893
[TBL] [Abstract][Full Text] [Related]
19. Hormonal effects of apomorphine in schizophrenia.
Ferrier IN; Johnstone EC; Crow TJ
Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
[TBL] [Abstract][Full Text] [Related]
20. Plasma HVA, neuroleptics, and dopaminergic plasticity.
Dávila R
Biol Psychiatry; 1989 Jan; 25(1):1-3. PubMed ID: 2563229
[No Abstract] [Full Text] [Related]
[Next] [New Search]
